Want to see WILYY full AI Analyst Report?
WILYY Stock Chart & Stats
$21.24
$0.00(0.00%)
At close: 4:00 PM EDT
$21.24
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$13.80 - $22.26
Previous CloseN/A
Volume30.00
Average Volume (3M)4.00
Market Cap
$8.89B
Enterprise Value$10.23K
Total Cash (Recent Filing)$1.33B
Total Debt (Recent Filing)$20.99B
Price to Earnings (P/E)38.1
Beta0.87
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.52
Shares Outstanding423,506,600
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)4.48
Price to Sales (P/S)1.92
P/FCF Ratio13.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Strong Gross MarginA ~75.6% gross margin indicates durable product economics and meaningful pricing power in hearing aids and consumables. High gross margins provide an enduring buffer to absorb ASP pressure, fund R&D and product rollouts, and support margin recovery once operating leverage normalizes.
Robust Cash Generation / FCF ConversionSustained free cash flow conversion (~84% of net income) and strong operating cash flow create durable internal funding for deleveraging, integration costs, and targeted investments. Reliable cash generation increases financial flexibility while management executes cost programs and M&A integration.
KIND Acquisition Strengthens Clinic FootprintClosing KIND materially expands Hearing Care scale, notably in Germany where management expects a market-leading position. The acquisition adds recurring clinic revenues, cross‑sell opportunities and service margins, structurally improving revenue mix and potential EBIT resilience over coming years.
Bears Say
Elevated Leverage After AcquisitionsGearing at ~3.4x (management target 2.0–2.5x) raises refinancing and interest rate vulnerability and forced a buyback pause. Elevated leverage limits strategic flexibility, increases debt service risk if earnings slip, and makes timely deleveraging execution critical to long‑term financial stability.
Weakened Operating And Net ProfitabilityMaterial margin deterioration reflects higher costs, mix shifts and lower operating leverage. Persistently lower EBIT and net margins would constrain free cash flow growth and reduce capacity to service debt or fund growth, making margin restoration central to durable financial recovery.
Market Softness And U.S. Share LossOngoing market softness, particularly flat U.S. demand and lost share to large retailers, is a structural headwind. Persistent competitive pressure and channel shifts can depress ASPs and volumes, prolonging margin recovery and complicating efforts to deleverage and meet EBIT targets.
Demant News
WILYY FAQ
What was Demant’s price range in the past 12 months?
Demant lowest stock price was $13.80 and its highest was $22.26 in the past 12 months.
What is Demant’s market cap?
Demant’s market cap is $8.89B.
When is Demant’s upcoming earnings report date?
Demant’s upcoming earnings report date is Aug 11, 2026 which is in 6 days.
How were Demant’s earnings last quarter?
Demant released its earnings results on Feb 03, 2026. The company reported $0.159 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Demant overvalued?
According to Wall Street analysts Demant’s price is currently Overvalued.
Does Demant pay dividends?
Demant does not currently pay dividends.
What is Demant’s EPS estimate?
Demant’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Demant have?
Demant has 423,506,600 shares outstanding.
What happened to Demant’s price movement after its last earnings report?
Demant reported an EPS of $0.159 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.588%.
Which hedge fund is a major shareholder of Demant?
Currently, no hedge funds are holding shares in WILYY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Demant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.36%
Trailing 12-Months
Company Description
Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
Technical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―